Suggested remit: To appraise the clinical and cost effectiveness of odevixibat within its marketing authorisation for treating cholestasis and pruritus in Alagille Syndrome.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6181

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
07 September 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
07 September 2023 Topic selection
07 September 2023 In progress
22 August 2023 The topic routing was considered by the Topic Selection Oversight Panel (TSOP) in July 2023. The panel concluded that the topic should be routed to the Technology Appraisal (TA) work programme. Please see project documents for further details
22 August 2023 Topic selection
16 August 2023 Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes.
05 May 2023 (10:00) Scoping workshop
15 March 2023 - 14 April 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
15 March 2023 In progress. Scoping Commenced.
11 October 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual